Korea’s 40th New Drug ‘Nuviju’ Launches: A Three-Way Battle for the Double-Chin Market
Medytox is set to shake up the aesthetic medicine industry with the launch of "Nuviju," a new treatment for submental (under-chin) fat, at the end of...
Search results for "Phase 3 trial"
ABL Bio to Present Two Bispecific Antibody ADC Posters at AACR
ABL Bio announced on the 19th that it will participate in this year’s American Association for Cancer Research Annual Meeting and present poster data...
HK inno.N’s ‘Ecnoglutide’: Can a Late Entrant’s “Hidden Card” Reshape the Obesity Market?
HK inno.N is fast-tracking the South Korean launch of ecnoglutide, a GLP-1 receptor agonist licensed from China’s...
A Single Cancer Shot: Local Injection Triggers Systemic Tumor Disappearance
For decades, one immuno-oncology strategy has held immense promise while repeatedly falling short: the use of CD40...
Idience Targeted Cancer Drug Candidate ‘Venadaparib’ Granted FDA Fast Track Designation
Idience, a novel anticancer drug developer under the Ildong Pharmaceutical Group, announced on the 18th that its...
Restoring the Breath of Night: The Potential for a Sleep Apnea Pill
Obstructive sleep apnea , a condition where breathing repeatedly stops during sleep, is far more than a mere snoring...
SK Chemicals Launches High-Dose 300 mg Joins for Osteoarthritis Treatment
SK Chemicals has announced the release of a new high-dose version of Joins, its flagship natural product-based...
Datroway Approved: New Targeted Therapy Offers Hope for Metastatic Breast Cancer
A new therapeutic horizon has arrived for patients battling metastatic breast cancer that has progressed despite...
The Unexpected Heart Benefits of Weight Loss Injections: Reducing Complications After Heart Attack
New research indicates that the class of drugs used in popular weight loss injections may do more than shed pounds;...
Rznomics to Present Oral Report on Breakthrough Anti-Cancer Gene Therapy at AACR
Rznomics, a biotechnology company specializing in RNA-based gene therapies, announced on March 5 that it has been...